The United Kingdom and the United States have reached a significant bilateral deal that will keep zero duties on UK medicine shipments being sold in the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to boost expenditure on drugs through the NHS. This move guarantees that tariffs on these vital products will stay at nothing for a timeframe of the next three years.
This agreement is in response to previous warnings to dramatically increase import taxes on patented pharmaceutical products, with figures floated as high as double the cost.
"This deal between the UK bolsters the global environment for innovative medicines and introduces long-overdue balance to American-British drug exports," a release noted.
Commercial Importance
Medicines are one of the Britain's largest goods shipped to the US, which is clearly the primary destination for major companies like GSK and AstraZeneca.
Trade data show that in the 12 months to the end of September, the UK exported medicines worth billions to the US. This figure accounted for a significant portion of all goods exports in that timeframe.
"This deal protects work, stimulates investment and facilitates the UK to emerge as a global hub for life sciences," a minister commented.
Specific British Pledges
The pact involves several key pledges from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it deems new medicines to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a aim to increase overall NHS spending on drugs from 0.3% of the national economy to 0.6% over the following ten-year period.
- Rebate Cap: The amount manufacturers must refund to the NHS to stay within budget will be limited at 15%. Previously, repayments exceeded twenty percent.
Recent Tensions
The deal follows a protracted row between the sector and the ministers over medicine costs and NHS adoption.
These tensions were exacerbated by claims that US consumers were paying significantly more for the identical medicines than people in the other developed nations.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or abandoned, while major funding commitments have been announced toward American operations.
The Science Minister acknowledged that the NHS had to increase expenditure on medicines, noting that its spending on drugs had declined as a proportion of its total funding over the previous ten-year period.
